@article{Hasan_Rabbani_Bachar_2019, title={Evaluation of the Therapeutic Effectiveness of Polymyxin B Versus Colistin in Carbapenem-resistanct Klebsiella pneumoniae-Associated Bacteremia}, volume={18}, url={https://www.banglajol.info/index.php/JPharma/article/view/43263}, DOI={10.3329/dujps.v18i2.43263}, abstractNote={<p>Polymyxins are the last resort antibiotics for treating carbapenem-resistance <em>Klebsiella pneumoniae </em>(CR-<em>Kp</em>)-associated bacteremia. The main aim of this study was to demonstrate the therapeutic effectiveness of polymyxin B versus colistin in the treatment of CR-<em>Kp</em>-associated Bacteremia. This 12-month long cross-sectional study was conducted on 54 and 47 patients suffering from CR-<em>Kp</em>-associated Bacteremia, and residing into two separate groups, they were treated with polymyxin B and colistin, respectively. After 5 day-treatment, the microbiological eradication rate was found 96.30% (52; n=54) in polymyxin B group and 87.23% (41; n=47) in colistin group. In the 30-day mortality rate-comparison, 51.03% more death was found in colistin group (34.04 %, n= 47) than the polymyxin B group (16.67 %, n= 54). In this study, Polymyxin B showed superior therapeutic potentiality with less number of secondary infections and 30-day mortality rate in CR-<em>Kp-</em>associated bacteremia than colistin.</p> <p>Dhaka Univ. J. Pharm. Sci. 18(2): 209-215, 2019 (December)</p>}, number={2}, journal={Dhaka University Journal of Pharmaceutical Sciences}, author={Hasan, Md Jahidul and Rabbani, Raihan and Bachar, Sitesh C}, year={2019}, month={Sep.}, pages={209–215} }